An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Trial Details

NCT ID

NCT06693973

Phase

EARLY_PHASE1

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• AcNK-Sup003 cell injection solution

Locations (sample)

• Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

• Signed an informed consent form in writing and is able to comply with the visits and related procedures specified in the protocol.
• Age ≥18 years old, with an expected survival of more than 3 months.
• Confirmed by pathology to have CD20+ relapsed or refractory B-cell non-Hodgkin's lymphoma (according to the WHO 2016 lymphoma classification standa…
• Relapsed or refractory disease, defined by one or more of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.